Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · SCHEDULE 13G/A

Traws Pharma, Inc.

TRAWNASDAQEQUITYCurrent

SEC Filing

Filed Aug 14, 2026Accepted Aug 14, 2026, 1:24 PM EDTCIK 1130598Accession 0002050709-26-000026
Share

Company context

Pharma, Inc. Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.

Current securities

Historical securities (2)

Recent company filings

  1. SCHEDULE 13G/A filingAug 14, 2026
  2. 10-Q filingAug 14, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureAug 14, 2026
  4. SCHEDULE 13G filingAug 14, 2026
  5. SCHEDULE 13G/A filingAug 12, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗